S3721 HCPCS code: Prostate cancer antigen 3 (pca3) testing
S3721 is the HCPCS Level II code for prostate cancer antigen 3 (pca3) testing. CMS terminated S3721 on 2015-12-31; do not bill it for later dates of service. Its Medicare coverage code is I (Not payable by Medicare): Medicare does not pay separately under this code; another code applies.
Code details
| Field | Value |
|---|---|
| Section | S codes — Temporary national codes (non-Medicare) |
| Coverage code | I — Not payable by Medicare |
| Pricing indicator | 00 — Not separately priced by Medicare |
| BETOS category | Z2 |
| Added | 2012-04-01 |
| Last action effective | 2016-01-01 |
| Terminated | 2015-12-31 |
What changed for S3721
- 2012-04-01: S3721 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code S3721?
S3721 is the HCPCS Level II code for prostate cancer antigen 3 (pca3) testing. Short descriptor: "Pca3 testing".
Does Medicare cover S3721?
Coverage code I — Not payable by Medicare. Medicare does not pay separately under this code; another code applies.
Related S37 codes
- S3708 — Gastrointestinal fat absorption study
- S3722 — Dose optimization by area under the curve (auc) analysis, for infusional 5-fluorouracil
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under S3721
- Watch S3721 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for S3721
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.